Outcome of lamotrigine treatment in juvenile myoclonic epilepsy

Acta Neurol Scand. 2011 Jul;124(1):22-7. doi: 10.1111/j.1600-0404.2010.01472.x. Epub 2011 Jan 6.

Abstract

Objectives: To determine the response rate of patients with juvenile myoclonic epilepsy (JME) to lamotrigine (LTG) and identify predictive factors for treatment response.

Material and methods: Medical records of 62 patients with JME were reviewed for demographic, clinical, and EEG parameters. We determined clinical response to LTG and compared LTG responders with non-responders.

Results: There were 35 LTG responders (56%) and 27 non-responders (44%). JME patients without generalized tonic clonic seizures (GTCS) responded better to LTG (P = 0.04). Valproic acid (VPA) failure because of adverse events rather than lack of efficacy (P = 0.069) and delay in diagnosis (P = 0.07) showed a tendency toward good response to LTG.

Conclusions: LTG should be considered a drug of first choice for JME patients without GTCS. LTG as second-line treatment after VPA failure seems more appropriate for those patients whose reason for VPA failure is poor tolerability rather than lack of efficacy.

MeSH terms

  • Adolescent
  • Anticonvulsants / therapeutic use*
  • Child
  • Female
  • Humans
  • Lamotrigine
  • Male
  • Myoclonic Epilepsy, Juvenile / drug therapy*
  • Prognosis
  • Retrospective Studies
  • Seizures / drug therapy*
  • Treatment Outcome
  • Triazines / therapeutic use*
  • Young Adult

Substances

  • Anticonvulsants
  • Triazines
  • Lamotrigine